What Baralgin M Treats: Main Uses and Benefits

Baralgin M (metamizole) is a medicine generally associated with pain relief that is commonly used to help with pain relief, temperature reduction, and easing smooth muscle spasms. This combination of actions is considered relevant in conditions involving episodic or fluctuating manifestations that require short-term symptomatic assistance.

The medicine is commonly used in situations involving certain distressing symptoms, such as significant discomfort and increased body temperature. The use is relevant in contexts presenting with systemic or localized discomfort, for example, discomfort associated with spasms, following procedures, or with certain types of colic.

It is considered relevant that the effects of the medication are applied in addressing symptoms that create noticeable physiological strain. By addressing symptoms related to physical discomfort and heightened physiological activity, it may contribute to easing the overall symptom burden and supports general well-being during symptomatic phases.

Quick Fact: May assist with easing symptoms related to physical discomfort

Regulatory References

1. European Medicines Agency therapeutic overview on metamizole

Who Can and Cannot Use Baralgin M? (Official Regulatory Information)

Baralgin M's eligibility profile is strictly defined by government regulatory documents, focusing on patient history, age, and physiological status.

Eligibility Status	Patient Groups and Conditions
Absolute Contraindication	History of agranulocytosis or blood disorders (e.g., impaired bone marrow function) related to pyrazolone derivatives. Third trimester of pregnancy. Infants below 3 months or less than 5 kg of body weight. Known analgesic-induced asthma or specific metabolic disorders (like acute intermittent hepatic porphyria).
Age-Related Eligibility	Generally approved for adults and adolescents 15 years and older. Use in younger children (down to 3 months/5 kg) is generally permitted, though fixed-dose tablets are not recommended for children under 10 or 15 due to dosing difficulties.
Conditional/Restricted Use	Pregnancy: Single doses during the first six months might be acceptable if other analgesics cannot be used. Breastfeeding is not recommended as a precaution. Organ Impairment: Dose reduction is necessary for the elderly and patients with impaired renal or hepatic function, and multiple high doses must be avoided.

Eligibility is defined by regulatory bodies to protect populations with high risk, such as those with prior haematological sensitivity or compromised circulatory stability.

Baralgin M (Sodium Metamizole) has officially documented interaction patterns that primarily involve changes in the metabolism and exposure of other medicines, as well as additive pharmacodynamic effects. These interactions are formally classified in regulatory documents.

Metamizole is documented as a moderate to strong inducer of several liver enzymes, including CYP3A4, CYP2B6, and CYP2C19. This enzyme induction may result in significantly decreased plasma concentrations of co-administered medicines. The regulatory profile states that co-administration leads to decreased serum levels of Ciclosporin, necessitating the official requirement that Ciclosporin concentration in the blood must be monitored.

Conversely, Metamizole is also noted as a moderate inhibitor of the enzyme CYP1A2. A clinically significant pharmacodynamic interaction involves low-dose Acetylsalicylic Acid (ASA) used for cardiovascular protection, where Metamizole may reduce the antiplatelet effect of ASA. This leads to the official recommendation that ASA be administered at least 30 minutes prior to Metamizole.

Co-administration also presents an additive risk for specific toxicities; concurrent use with Methotrexate carries an officially noted additive risk for haematologic toxicity. A risk of additive hypothermia is documented when Metamizole is combined with Chlorpromazine. Use is formally contraindicated in infants below 3 months or 5 kg of body weight.

How Baralgin M Works

The actions of the drug involve two distinct and complementary mechanistic domains: one focused on the central nervous system and another involving direct modulation of involuntary muscles.

Central Modulation of Nociceptive Signaling and Thermoregulation

The primary action of the active metabolites involves the inhibition of cyclooxygenase (COX) enzymes, specifically within the central nervous system. By selectively reducing the synthesis of prostaglandins in the brain and spinal cord, the drug alters the pathway that controls nociceptive signaling and thermoregulation. This biochemical change results in the elevation of the central nociceptive threshold and modulation of the hypothalamic thermoregulatory set-point.

Direct Visceral Smooth Muscle Relaxation

This mechanism involves a direct, non-prostaglandin-mediated modulatory effect on the smooth muscle fibers of internal organs, such as the intestines, bile ducts, and urinary tract. This action reduces the muscle's excitability and tension. By relaxing the walls of these organs, the mechanism results in the reduction of excessive muscle tone and contraction (antispasmodic effect), which contributes to the drug’s overall physiological action.

Metabolic Activation

The administered substance is transformed within the body into active metabolites that are responsible for the full mechanistic effect. This metabolic process is required for the active compounds to engage the biological targets, initiating the inhibition of central COX enzymes and modulating smooth muscle tone.

Instruction Map: How to use Baralgin M — Administration Guidelines

This map consolidates the administration and dosing instructions for Baralgin M (Sodium Metamizole).

Administration Scope

Route of administration: Oral (tablets, drops/solution), Intravenous (IV), Intramuscular (IM), and Rectal (suppository) administration are approved methods.

Dosing schedule:

• Adult Single Dose (ge 15 years): Oral doses should not exceed 1,000 mg. Parenteral doses (IV/IM) can be up to 2,500 mg depending on the acute need.
• Frequency: Doses can be administered up to four times daily, maintaining an interval of 6 to 8 hours between administrations.
• Maximum Daily Dose: Total daily dose must not exceed 4,000 mg for the oral route or 5,000 mg for the parenteral route.

Preparation requirements (if applicable): For the injectable solution, administration must be performed very slowly. The intravenous injection rate must not exceed 1 ml/minute. The solution may be mixed and administered immediately if diluted with approved solutions like 0.9% saline.

Age-group administration rules:

• Pediatric Patients (le 14 years): Dosing must be determined based on body weight, typically ranging from 8–16 mg per kilogram of body weight as a single dose.
• Older Adults/Impaired Function: Dose reduction is required in older individuals and patients with reduced creatinine clearance due to the prolonged elimination of metabolic products.

Special procedural conditions: Administration is generally limited to short-term use, consistent with the protocol for acute symptomatic relief.

Instruction Classifications (High-Level)

Administration method type (oral / IV / topical / inhaled / etc.): Multi-route

Frequency pattern (daily / weekly / as-needed, etc.): Intermittent, As-Needed

Regulatory basis: Standardized Protocol

Use-context constraints: Short-term use

Resulting Procedural Structure

Official step sequence:

• The lowest effective dose is selected for the appropriate route (Oral, IV, IM, or Rectal) and calculated by weight for pediatric patients.
• Dosing is limited to a maximum of four times per day, ensuring a minimum interval of 6 to 8 hours between doses.
• Parenteral administration requires strict control over the injection rate, not exceeding 1 ml/minute.

Connection to the overall use protocol (2–4 sentences): These instructions establish a standardized, multi-route administration protocol that is tied to maximum dose limits and time intervals, defining the full course of use. The protocol involves adherence to these figures, particularly the slow rate for intravenous administration and the body-weight-based calculations for younger populations. This procedural framework guides the proper use of the medicine.

Research Evidence / Overview of Studies

Baralgin M, containing the active ingredient metamizole (also known as dipyrone), has been the subject of numerous clinical trials and systematic reviews, primarily focusing on its role as an analgesic (pain reliever) and antipyretic (fever reducer).

Efficacy in Pain and Fever

Clinical data support the use of metamizole in treating severe acute pain, including post-operative pain, colic pain, and tumor-related pain. Randomized controlled trials (RCTs) have frequently compared its efficacy against other common analgesics, such as ibuprofen and diclofenac. A review of studies focused on acute post-operative pain indicated that a single 500 mg dose of metamizole provided pain relief comparable to established therapies in a significant proportion of participants over four to six hours.

Studies also consistently show metamizole's effectiveness in reducing high fever, including cases refractory (unresponsive) to first-line agents like paracetamol (acetaminophen) and ibuprofen, with some analyses indicating a comparable antipyretic effect to these alternatives in pediatric and adult populations.

---

Safety and Adverse Events Profile

Ongoing clinical research and regulatory reviews, such as those conducted by the European Medicines Agency (EMA), have continuously evaluated the benefit-risk ratio. The most widely discussed adverse event is the rare but serious risk of agranulocytosis (a severe reduction in certain white blood cells). Recent incidence data from large-scale studies and registries vary widely by region, but confirm the risk is low, though potentially life-threatening.

Adverse Event (AE)	Clinical Finding in Trials
Agranulocytosis	Rare; occurs at an estimated rate of approximately 0.6 to 2 cases per million daily users (regional variation acknowledged).
Common AEs	Gastrointestinal disturbances and allergic reactions (e.g., rash), generally reported less frequently than with some traditional NSAIDs.
Liver Injury	Cases of acute liver injury have been reported, varying in presentation from hyper-acute to delayed onset; recovery is often rapid upon cessation.

Common questions about Baralgin M (FAQ)

Q: What is Baralgin M typically used for?

Baralgin M contains metamizole, which is indicated for the management of severe pain and high fever when other treatment options are not suitable. Its use is subject to varying regulatory approval across different regions.

Q: How does Baralgin M work?

Baralgin M's active ingredient, metamizole, is understood to work by influencing pain and fever pathways in the central nervous system. The precise mechanism is complex and still under study.

Q: What are the main risks associated with Baralgin M?

A primary concern associated with metamizole is the potential for a rare but serious blood disorder called agranulocytosis. Other potential side effects may include allergic reactions and low blood pressure. Patients are generally advised to be aware of symptoms and consult a healthcare provider immediately if they occur.

Storage and Disposal of Baralgin M (Metamizole)

Official regulatory guidelines define specific conditions for storing and discarding Baralgin M to maintain product stability and safety.

Storage Scope	Regulatory Requirements
Temperature & Light	Injection solutions must be stored not above 25, C and protected from light. Do not store the injection solution in the freezer.
Container & Access	Keep the medicine in the original container, tightly closed, and strictly out of the reach and sight of children and pets.

Disposal must adhere to official protocols. The preferred method for unused or expired oral forms is through a drug take-back program.

If a program is unavailable, non-liquid forms should be mixed with an undesirable substance (e.g., used coffee grounds) and placed in a sealed container before discarding in the trash. Unused injection solutions must be discarded according to standard procedures for biohazardous waste.